Company News

This product portfolio comprises eight chemically defined building blocks positioned along the industrial synthesis of Enzalutamide (Xtandi®), a second-generation androgen receptor antagonist approved for metastatic castration-resistant prostate cancer.

This product portfolio comprises four chemically defined building blocks positioned along the industrial synthesis of Bicalutamide (Casodex®), a non-steroidal antiandrogen widely prescribed for prostate cancer.

The three compounds—trans-1,2-Cyclohexanedicarboxylic acid, (1R,2R)-1,2-Cyclohexanedicarboxylic acid, and (1R,2R)-1,2-Cyclohexanedimethanol—represent a progressive synthetic cascade: the racemic trans-diacid serves as the starting material for chiral resolution, the enantiopure (1R,2R)-diacid is the resolved chiral building block, and the (1R,2R)-diol is the reduced, activated form ready for mesylation and final coupling.

Pregabalin is a chiral γ-aminobutyric acid (GABA) analog that functions as a calcium channel modulator, clinically indicated for neuropathic pain and as adjunctive therapy for partial-onset seizures. Structurally, Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid, a branched aliphatic amino acid bearing an isobutyl side chain at the β-position and an aminomethyl group at the α-position.

Cosperpharm now offers a comprehensive portfolio of key intermediates for Daraxonrasib (RMC-6236), providing one-stop supply chain support for the development of this oral RAS(ON) multiselective inhibitor.

Cosperpharm now offers a comprehensive portfolio of key intermediates for MK-0616 (Enlicitide chloride), providing one-stop supply chain support for generic and innovative drug development of the oral PCSK9 inhibitor.